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Summary Current standard of care following a percutaneous coronary intervention with stent
placement necessitates the use of dual anti-platelet therapy with aspirin and commonly clopido-
grel. There is a subset of patients who have a signiﬁcant clopidogrel allergy and life-threatening
hypersensitivity reactions. Desensitization is the process of inducing tolerance to a sensitizingPCI agent via repeated exposure to the agent. There have been previously reported protocols for
clopidogrel desensitization. These protocols differ in length and dose escalation and a univer-
sally accepted clopidogrel desensitization protocol has yet to be established. We discuss here
a novel accelerated approach to clopidogrel desensitization in a patient with a documented
hypersensitivity reaction.
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urrent standard of care necessitates the use of clopido-
rel following a coronary artery percutaneous intervention
ith stent placement. There is a small subset of patients
ho have a signiﬁcant clopidogrel allergy. We discuss here a
ovel, accelerated approach to clopidogrel desensitization
n a patient with a documented clopidogrel allergy.
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ase presentation
78-year-old man presented to our clinic with recurrent
pisodes of chest pressure with exertion. The patient had a
ast medical history of hypertension, dyslipidemia, chronic
idney disease, and coronary artery disease with a sep-
al wall myocardial infarction in 2001. At that time he
nderwent cardiac catheterization and was found to have
signiﬁcant left anterior descending artery stenosis andnderwent balloon angioplasty with stent placement. As a
tandard of care, the patient was started on 75mg of clopi-
ogrel immediately after the stent placement. He tolerated
he ﬁrst dose with no difﬁculties and was discharged home
he day following the procedure. The following day at home,
Published by Elsevier Ireland Ltd. All rights reserved.
sitivity reaction e159
Table 1 Clopidogrel desensitization protocol.
A clopidogrel 75-mg tablet was compounded in 1000mL
of sterile distilled water with the ﬁnal resulting
concentration of 0.075mg per mL concentration. Oral
syringes were drawn with the following concentrations
and administered at 15-min intervals
Time from initiation
(in min)
Dose
(in mg)
Dose
(in mL)
0 0.0075 0.1
15 0.015 0.2
30 0.03 0.4
45 0.06 0.8
60 0.12 1.6
75 0.24 3.2
90 0.48 6.4
105 0.96 12.8
120 1.92 25.6
135 3.84 51.2
150 7.68 102.4
After the ﬁnal oral syringe was administered, a 75-mg
tablet was spilt as follows again with 15min spacing
in-between dose escalation
165 18.75
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fNovel, accelerated desensitization for clopidogrel hypersen
he took another 75mg dose of clopidogrel. Two hours after
this dose, he developed diffuse skin erythema and pruri-
tus. There was no skin desquamation, no facial edema, no
oral lesions, and no anaphylaxis. The patient did go to an
emergency room because of these symptoms. In the emer-
gency room, he was treated with 100mg of IV and 50mg of
diphenhydramine orally. These resolved his symptoms within
1 h. Due to the improvement with methylprednisolone and
diphenhydramine, the patient was deemed to have a clopi-
dogrel allergy and this medication was stopped.
He returned to the cardiology clinic 8 years later with
a 3-day history of shortness of breath with exertion. He
could only walk for 5min after which he became short of
breath, had to sit down, rest and take deep, slow breaths.
His symptoms would slowly subside after 5min. He recounts
that sometimes his shortness of breath was associated with
a retro-sternal, moderately intense, chest pressure that
radiated to his inner left arm, and lasted about 1—2min.
Previous to this, the patient was very active and walked at
least two miles every day with no symptoms.
The patient’s medications included metoprolol succi-
nate, pravastatin, ﬂuoxetine, captopril, aspirin, tamsulosin,
and ﬁnasteride.
The patient was admitted to hospital for evaluation of
his unstable angina. His initial exam showed that he was
in normal sinus rhythm and his blood pressure was at goal.
He was lying comfortably in bed, had no jugular venous dis-
tention, his lungs were clear to auscultation bilaterally, the
cardiac exam was signiﬁcant for a II/VI systolic murmur at
the right sternal border which was non-radiating, and the
lower extremities did not reveal any edema.
The laboratory exam was signiﬁcant for hemoglobin
of 15.5 g/dL, blood urea nitrogen of 25mg/dL, creati-
nine of 1.5 g/dL, total cholesterol of 152 g/dL, high-density
lipoprotein cholesterol of 29mg/dL, low-density lipoprotein
cholesterol of 61mg/dL, and triglycerides of 312mg/dL. His
cardiac biomarkers initially showed a creatine kinase (CK)
MB of less than 0.22 units/L and troponin I 0.075 ng/mL (nor-
mal at our institution being less than 0.03 ng/mL), with
repeat cardiac enzymes 8 h later showing a CKMB of less
than 0.22 units/L and a troponin I that had increased to
0.110 ng/mL.
His electrocardiogram showed normal sinus rhythm and
evidence of an old inferior infarction, but no evidence of
ischemia or acute injury.
Based on the nature of his symptoms, the patient was
treated for unstable angina and in addition to his home med-
ications he was given enoxaparin 1mg/kg subcutaneously
bid. The following day, the patient was taken to the car-
diac catheterization lab to evaluate for progression of his
coronary artery disease.
The coronary angiography showed the left anterior
descending (LAD) artery had a signiﬁcant 99% stenosis in the
proximal segment and an 80% stenosis in the distal segment.
The remainder of the coronary arteries had mild-moderate
disease. It was thought that the LAD artery stenoses were
the culprit for the patient’s symptoms. A cutting balloon was
used on the proximal segment with a residual 30% steno-
sis. The most appropriate intervention was deemed to be
a stent to the proximal and distal LAD stenoses. However,
due to the necessity to administer clopidogrel after stenting,
the patient was taken back to his room to be desensitized
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o clopidogrel and then subsequent percutaneous coronary
ntervention with stenting to the LAD. We hypothesized
novel approach for inpatient clopidogrel desensitization
rior to coronary angioplasty.
Epinephrine, diphenhydramine, and methylprednisolone
ere all available at the patient’s bedside. The patient was
n the coronary care unit under continuous telemetry moni-
oring by a critical care nurse and physician during the entire
rotocol. Desensitization was begun using the following pro-
ocol (Table 1).
A percutaneous coronary intervention with bare-metal
tent placement was scheduled for the following day. Cur-
ent practice guidelines recommend a loading dose of
00—600mg of clopidogrel to be administered prior to the
rocedure to obtain maximal platelet inhibition. A modiﬁed
lopidogrel loading dose was given. The patient had received
pproximately 71.6mg as part of the desensitization pro-
ocol, plus an additional 75mg for a total of 146.6mg. An
dditional 150mg of clopidogrel was given the following day
rior to cardiac angioplasty for a total load of 296.6mg of
lopidogrel administered within 24 h prior to stent place-
ent.
The desensitization protocol was completed without any
vents. Our patient did not develop any maculopapular
ash or urticaria. He did not complain of itching, shortness
f breath, or swelling. He remained stable and chest-pain
ree. After the desensitization, his medications, including
he beta-blocker, statin, aspirin, and angiotensin-converting
nzyme inhibitor were restarted. The patient was sched-
led for cardiac catheterization with stent placement 24 h
fter desensitization. The patient underwent successful per-
utaneous coronary intervention with a bare-metal stent
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3.0mm× 24mm) to the proximal LAD. The procedure was
ell tolerated with 0% residual stenosis. After the proce-
ure, the patient was placed on aspirin 325mg daily and
lopidogrel 75mg daily in addition to his home medications.
e remained stable with no pruritus, rash, chest discomfort,
r respiratory complaints. The patient was discharged 24 h
fter his procedure with follow up in the cardiology clinic.
t 1-, 3-, and 6-month follow up visits, the patient was still
aking clopidogrel and had no signs or symptoms of allergy
r other complications.
iscussion
remature discontinuation of aspirin and thienopyridines
as been associated with major adverse events, including
tent thrombosis [1]. Approximately 4% of the popula-
ion has been reported to have potential allergic reactions
o clopidogrel, necessitating discontinuation of the medi-
ation. Ticlopidine, the other thienopyridine available at
he time, has fallen out of favor due to cost, more fre-
uent dosing, and its association with more frequent and
erious side-effect proﬁle including blood dyscrasias and
hrombotic thrombocytopenic purpura [2]. Since the ini-
ial presentation of the patient, the US Food and Drug
dministration has approved a new thienopyridine, prasug-
el. Due to structural similarities, it is felt that allergic
ross-reactions may occur with prasugrel as well as ticlopi-
ine. Also, it has been reported that in clopidogrel-allergic
atients switched to ticlopidine, 27% of them developed
cross-reaction [3]. Cilostizol may be a safe alternative,
nd this was considered in the patient’s management. How-
ver, the data for stenting and cilostizol is not nearly
s robust as it is with clopidogrel. It was assumed that
t least a component of the patient’s previous reaction
as IgE mediated, since the initial allergic reaction was
apid and responded to methylprednisolone and diphenhy-
ramine.
Desensitization is the process of inducing tolerance to a
ensitizing agent via repeated exposure to the agent. This is
ccomplished by exposing the patient to escalating doses of
drug in a monitored setting until a therapeutic dose can be
olerated without reaction. The precise immunologic mech-
nism by which rapid oral desensitization procedures work
s both complex and incompletely deﬁned, but the funda-
ental effect is the induction of antigen-speciﬁc mast cell
olerance [4—6]. Desensitization may allow for the use of
lopidogrel as part of dual anti-platelet therapy in hyper-
ensitive patients with recent or planned coronary stent
mplantation or for secondary prevention of cardiovascu-
ar events. Established desensitization protocols exist for
any medications, but there is no universally accepted pro-
[R. Doshi et al.
ocol for clopidogrel desensitization. Published techniques
or clopidogrel desensitization have used dose escalation
very 30min for an inpatient protocol over a 7-h period
7,8] to an outpatient regimen lasting over seven and a half
ours, again with increasing doses every 30min. Our sug-
ested technique is a novel, accelerated protocol that can
e accomplished in the inpatient setting with doubling the
ose given every 15min allowing complete desensitization in
nly 3 h and 15min. This shortened technique may facilitate
he possibility of desensitizing a patient in the morning and
hen performing a percutaneous coronary intervention with
tent placement later that same day, thus reducing hospital
tay and expense [9].
onclusions
n summary, we introduce a safe, novel, accelerated desen-
itization protocol for use in patients with a hypersensitivity
eaction to clopidogrel. Further application to additional
ases would be necessary to establish universal acceptance.
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